A股異動丨愛施德一字漲停 引入阿里巴巴作為戰略投資者
格隆匯4月27日丨愛施德(002416.SZ)一字漲停,封單近180萬手。現報7.79元,暫成交1665萬元,最新總市值96.54億元。愛施德26日公告,公司將以非公開發行的方式向認購方阿里巴巴發行7910.3萬股,新股的每股認購價格為人民幣5.1459元。同時,雙方擬成立合資公司,共同推進智能終端領域的數字化新分銷和新零售業務創新合作,雙方擬阿里巴巴持股51%、愛施德持股39%、廣東新聯持股10%。雙方的戰略合作,通過技術賦能,能夠幫助愛施德實現供銷體系的數字化升級,顯著增強其核心競爭力和創新能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.